Item 8.01 Other Events

On June 21, 2022, Zynerba Pharmaceuticals, Inc. (the "Company") issued a press release announcing positive top line results from the open-label Phase 2 INSPIRE trial of Zygel in 22q11.2 Deletion Syndrome. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Attached as Exhibit 99.2 is a slide presentation that the Company posted on its website on June 21, 2022 and may use from time to time in presentations or discussions with investors, analysts and other parties.

Item 9.01 Financial Statements and Exhibits

The following exhibit is being filed herewith:



(d) Exhibits



Exhibit
No.                                       Document

  99.1       Press Release, dated June 21, 2022
  99.2       Zynerba Pharmaceuticals, Inc. Investor Presentation
104        The cover page from this Current Report on Form 8-K, formatted in
           Inline XBRL

© Edgar Online, source Glimpses